Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  New England Journal of Medicine

• Publication date

  2009-08-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa0809003PMID 19671656PMCID PMC3038121
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics

  2011cited by this paper
• [EAU guidelines on prostate cancer].

  2009cited by this paper
• Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

  2008cited by this paper
• Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial

  2008cited by this paper
• Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

  2008cited by this paper
• Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?

  2008cited by this paper
• Re: Axel Heidenreich, Gunnar Aus, Michel Bolla, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.

  2008cited by this paper
• Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

  2007cited by this paper
• Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

  2007cited by this paper
• Zoledronic acid and secondary prevention of fractures.

  2007cited by this paper
• Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

  2007cited by this paper
• Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

  2006cited by this paper
• Denosumab in postmenopausal women with low bone mineral density.

  2006cited by this paper
• Is it ethical to use placebos in osteoporosis trials?

  2006cited by this paper
• Risk of fracture after androgen deprivation for prostate cancer.

  2005cited by this paper
• Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline.

  2005cited by this paper
• Risk of fracture after androgen deprivation for prostate cancer.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Androgen deprivation therapy for prostate cancer.

  2005cited by this paper
• Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy

  2005cited by this paper
• Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

  2005cited by this paper
• Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

  2004cited by this paper
• Toremifene citrate versus placebo for treatment of bone loss and other complications of androgen deprivation therapy in patients with prostate cancer.

  2004cited by this paper
• Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy

  2004cited by this paper
• Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer

  2004cited by this paper
• Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.

  2004cited by this paper
• Fracture risk following bilateral orchiectomy.

  2003cited by this paper
• Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

  2003cited by this paper
• BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long‐Term Results From the Study of Osteoporotic Fractures

  2003cited by this paper
• Study Designs in Osteoporosis

  2003cited by this paper
• Is It Ethical to Conduct Placebo‐Controlled Clinical Trials in the Development of New Agents for Osteoporosis? An Industry Perspective

  2003cited by this paper
• The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis

  2003cited by this paper
• Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

  2002cited by this paper
• Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

  2001cited by this paper
• EAU Guidelines on Prostate Cancer

  2001cited by this paper
• EAU guidelines on prostate cancer.

  2001cited by this paper
• Alendronate for the treatment of osteoporosis in men.

  2000cited by this paper
• Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

  1999cited by this paper
• Adjuvant Hormonal Treatment with Radiotherapy for Locally Advanced Prostate Cancer

  1998cited by this paper
• Adjuvant Hormonal Treatment with Radiotherapy for Locally Advanced Prostate Cancer.

  1998cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper

• The interrelationship between prostate cancer and osteoporosis: new perspectives on shared molecular pathways and treatment strategies.

  2026cites this paper
• Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

  2026cites this paper
• Drug-Induced Osteoporosis

  2026cites this paper
• Bone health in patients with cancer: a SEOM-SEIOMM consensus review of risk factors, assessment strategies, and management approaches.

  2026cites this paper
• A Randomized Phase 1 Study Comparing the PK, PD, Safety, and Immunogenicity of Proposed Biosimilar RGB‐14‐X and Denosumab in Healthy Adult Males

  2026cites this paper
• Two cases of tooth resorption in patients receiving denosumab therapy.

  2026cites this paper
• Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti‐Oestrogen Therapy for Breast Cancer

  2025influential citation
• A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis

  2025cites this paper
• Molecular targeted therapies, omics, and AI based theranostics approaches for the treatment of prostate cancer.

  2025cites this paper
• 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

  2025cites this paper
• 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update).

  2025cites this paper
• A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population

  2025cites this paper
• Bone Health in Metastatic Hormone-Sensitive Prostate Cancer: Where We Stand and Where We Can Improve

  2025cites this paper
• Wissenswertes zur medikamentösen Osteoprotektion in der Uroonkologie

  2025cites this paper
• PRevEnting FracturEs in REnal Disease-1 (PREFERRED-1): protocol for a pilot study of a pragmatic, randomised controlled trial of denosumab for the prevention of fragility fractures in haemodialysis

  2025cites this paper
• Risk-adapted durations of hormone therapy combined with radiotherapy for prostate cancer

  2025cites this paper
• Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes

  2025cites this paper
• Osteoporosis in Men: an Overlooked Patient Population

  2025cites this paper
• BioBERT-powered synergy: advanced bibliometric and molecular insights into prostate cancer bone metastasis

  2025cites this paper
• Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach

  2025cites this paper
• Management and mitigation of metabolic bone disease and cardiac adverse events throughout the prostate cancer pathway: clinical review and practical recommendations

  2025influential citation
• Osteoporose beim Mann – eine unterschätzte Nebenwirkung des Hormonentzugs beim Prostatakarzinom

  2025cites this paper
• Personalized intensification of treatment for hormone-sensitive prostate cancer

  2025cites this paper
• Impact of Bisphosphonates in Hormone-sensitive Metastatic Prostate Cancer A Systematic Review and Meta-Analysis.

  2025cites this paper
• The efficacy and safety of denosumab, risedronate, alendronate and teriparatide to treat male osteoporosis: a systematic review and bayesian network meta-analysis

  2025cites this paper
• Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures

  2025cites this paper
• Packing the Punch: Current and Emerging Treatment Strategies in Metastatic Castration-Sensitive Prostate Cancer

  2025cites this paper
• Controversies in metastatic hormone‐sensitive prostate cancer

  2025influential citation
• Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial.

  2025cites this paper
• Metabolic Bone Disease in Pediatric Patients with Short Bowel Syndrome

  2025cites this paper
• Osteoporosis masculina

  2025cites this paper
• Fragility of Evidence for the Efficacy of Anti-Fracture Medications

  2025cites this paper
• Urinary calcium and bone resorption markers during 3 years of denosumab treatment in pediatric osteogenesis imperfecta

  2025cites this paper
• Frakturprävention mit Zoledronat bei postmenopausalen Frauen

  2025cites this paper
• From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008–2023)

  2025cites this paper
• Bone turnover markers as predictors of hypocalcemia in patients with bone metastases receiving denosumab

  2025cites this paper
• Symptom Burden and Survivorship Care for Patients With Prostate Cancer on Androgen Deprivation Therapy.

  2024cites this paper
• Exploring Denosumab in the Treatment of Giant Cell Tumors: Clinical Evidence and Controversies

  2024cites this paper
• Repurposing of PSMA-targeted diagnostic and therapeutic agents for the detection and treatment of giant cell tumors of bone

  2024cites this paper
• Osteopenia: a key target for fracture prevention.

  2024cites this paper
• Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle

  2024cites this paper
• Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study

  2024cites this paper
• Alendronate for Effective Treatment of Male Osteoporosis : An Insight.

  2024cites this paper
• Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

  2024cites this paper
• The use of denosumab in osteoporosis – an update on efficacy and drug safety

  2024cites this paper
• Prostate tissue ablation and drug delivery by an image-guided injectable ionic liquid in ex vivo and in vivo models

  2024cites this paper
• Impact of Androgen Deprivation Therapy on Lumbar Spine Bone Health Using Quantitative Computed Tomography in a Propensity-Matched Cohort of Patients With Prostate Cancer

  2024cites this paper
• Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management.

  2024cites this paper
• Role of osteoclast inhibitors in prostate cancer bone metastasis; a narrative review

  2024cites this paper
• High‐dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT

  2024cites this paper
• Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials.

  2024cites this paper
• Management of cancer treatment–induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey

  2024cites this paper
• Insights and implications of sexual dimorphism in osteoporosis

  2024cites this paper
• Cancer treatment-induced bone loss

  2024cites this paper
• Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan

  2024cites this paper
• Osteoporosis in older men

  2024cites this paper
• Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS

  2024cites this paper
• Bone health management in endocrine-treated patients with prostate cancer: a summary of evidence

  2024cites this paper
• S3-Leitlinie Heimenterale und heimparenterale Ernährung der Deutschen Gesellschaft für Ernährungsmedizin (DGEM)

  2024cites this paper
• Medication-induced Fractures: Screening and Treatment Strategies.

  2024cites this paper
• Antiresorptive Therapy Initiating After Stereotactic Body Radiotherapy for Spinal Metastasis: Less is More?

  2023cites this paper
• Efficacy of anti-osteoporosis treatment for men with osteoporosis: a meta-analysis

  2023cites this paper
• Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications

  2023cites this paper
• Efficacy and safety of COVID-19 vaccines for patients with spinal tumors receiving denosumab treatment: An initial real−clinical experience study

  2023cites this paper
• Dual‐energy x‐ray absorptiometry assessment of bone health in Australian men with prostate cancer commencing androgen deprivation therapy

  2023cites this paper
• How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?

  2023cites this paper
• Antiresorptive Medications Prior to Stereotactic Body Radiotherapy for Spinal Metastasis are Associated with Reduced Incidence of Vertebral Body Compression Fracture

  2023cites this paper
• Management of bone loss due to endocrine therapy during cancer treatment

  2023cites this paper
• The Role of Cytokines in the Metastasis of Solid Tumors to the Spine: Systematic Review

  2023cites this paper
• A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis

  2023cites this paper
• What Is Known about Breast Cancer in Young Women?

  2023cites this paper
• [Prostate Cancer: Side-Effect Management for Androgen Deprivation Therapy].

  2023cites this paper
• Prosztatarákos betegek csontegészségének megőrzése az onkológiai kezelés során

  2023cites this paper
• Pathogenesis and treatment of osteoporosis in patients with hemophilia

  2023cites this paper
• Biologic Antiresorptive: Denosumab

  2023influential citation
• Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase III Randomized Controlled Trial.

  2023cites this paper
• Long-term and sequential treatment for osteoporosis

  2023cites this paper
• Einfluss von Zoledronat und Denosumab auf humane Zellen der osteoblastären Linie aus dem Kieferknochen anhand osteogener Marker

  2023cites this paper
• Alzheimer’s disease and its associated risk of bone fractures: a narrative review

  2023cites this paper
• A Comprehensive Review of Interventional Clinical Trials in Patients with Bone Metastases

  2023influential citation
• Effects of Soft Tissue Sarcoma and Doxorubicin on Bone Metabolism in Mice

  2023cites this paper
• A Comprehensive Review of Differences between Osteoradionecrosis and Medication-related Osteonecrosis of the Jaw

  2023cites this paper
• Recent advances and future perspectives in the therapeutics of prostate cancer

  2023cites this paper
• Rare tumors: a blue ocean of investigation

  2023cites this paper
• Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer

  2023cites this paper
• Haemophilia and Fragility Fractures: From Pathogenesis to Multidisciplinary Approach

  2023cites this paper
• The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis

  2023cites this paper
• Osteometabolic changes in patients under antineoplastic treatment: scoping review

  2023cites this paper
• Bone health and therapeutic agents in advanced prostate cancer.

  2022cites this paper
• Low Bone Mineral Density in Hemophiliacs

  2022cites this paper
• LYTIC LESION OF A DIGIT COULD BE A METASTASIS FROM LUNG. A RARE CASE REPORT.

  2022cites this paper
• Regarding: Increased fracture risk after discontinuation of anti‐osteoporosis medications among hip fracture patients

  2022cites this paper
• Osteoporosis in men.

  2022cites this paper
• Osteoprotektion als Baustein der Therapie des metastasierten Prostatakarzinoms: Behandlungsrealität in Deutschland und Entscheidungspfade zur Therapieoptimierung

  2022cites this paper
• Discontinuation of denosumab in men with prostate cancer

  2022cites this paper
• Male osteoporosis

  2022cites this paper
• Osteoprotektion beim nichtmetastasierten hormonsensitiven Prostatakarzinom (nmHSPC) unter androgendeprivativer Therapie (ADT): Aktuelle Daten aus Deutschland, vorgelegt von d-uo

  2022cites this paper
• Withdrawal of Denosumab in Patients with Primary Hyperparathyroidism: A Follow-up Report of the DENOCINA-Study.

  2022cites this paper
• 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

  2022cites this paper
• Osteoprotektion beim ossär metastasierten kastrationsresistenten Prostatakarzinom (mCRPC): Aktuelle Daten aus Deutschland, vorgelegt von d-uo

  2022cites this paper